Chan Zuckerberg Biohub Choose Geneious For Best Practice NGS Antibody Pipeline

AUCKLAND, New Zealand, April 8, 2019 /PRNewswire-PRWeb/ -- To support the global fight against existing and emerging infectious disease, the innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has chosen Geneious Biologics to help them analyze and compare human antibody repertoires. The study of antibody repertoires is part of CZ Biohub's efforts to establish new approaches to inform the discovery of antibody-based diagnostics, new therapies and the design of recombinant protein vaccines. Together with collaborators, CZ Biohub and Geneious are working towards standardizing the analysis and use of immune receptor repertoire data.

Krista McCutcheon Group Leader, Antibody Discovery at CZ Biohub: "The commitment, expertise and collaborative nature of the Geneious team has allowed us to deliver on our internal goal of providing a software pipeline for NGS antibody data analysis and visualization aligned with the best practices in the field."

Geneious Biologics is Biomatters' cloud-based enterprise software solution for analysis of antibodies and related constructs using NGS or Sanger sequence data. The CZ Biohub are profiling B cell repertoires circulating in human blood in order to understand the history, evolution, memory, and molecular determinants of successful and failed immune responses to pathogens. The Antibody Discovery group then aims to identify and elicit defined specificities of memory B cells to protect diverse human populations around the globe.

Biomatters CEO Brett Ammundsen: "We are delighted to have been chosen by the CZ Biohub to support their mission to solve big health problems, particularly because of their philosophy of using the best scientific tools available. CZ Biohub is setting the standard for the industry and it's fantastic to be playing a role in that."

About Geneious and Biomatters
Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights across the spectrum of biotechnology research and development, including drug discovery, protein engineering and advanced comparative analysis of DNA, RNA and protein sequences. Geneious solutions are created from a deep understanding of customer experience and turn the difficult into the intuitive and easy. That is why Geneious is trusted by over 4,000 companies, universities and institutes all over the globe. https://www.geneious.com/

About the Chan Zuckerberg Biohub
The CZ Biohub is an independent non-profit medical research organization collaborating with the University of California, Berkeley, Stanford University and the University of California, San Francisco. The organization's goal is to harness the power of science, technology and human capacity to cure, prevent or manage all disease during our children's lifetime. For more information about the CZ Biohub, visit https://czbiohub.org.

SOURCE Geneious